TY  - JOUR
AU  - Pölzl, Gerhard
AU  - Altenberger, Johann
AU  - Baholli, Loant
AU  - Beltrán, Paola
AU  - Borbély, Attila
AU  - Comin-Colet, Josep
AU  - Delgado, Juan F
AU  - Fedele, Francesco
AU  - Fontana, Antonella
AU  - Fruhwald, Friedrich
AU  - Giamouzis, Gregory
AU  - Giannakoulas, George
AU  - Garcia-González, Martín J
AU  - Gustafsson, Finn
AU  - Kaikkonen, Kari
AU  - Kivikko, Matti
AU  - Kubica, Jacek
AU  - von Lewinski, Dirk
AU  - Löfman, Ida
AU  - Malfatto, Gabriella
AU  - Manito, Nicolás
AU  - Martínez-Sellés, Martin
AU  - Masip, Josep
AU  - Merkely, Bela
AU  - Morandi, Fabrizio
AU  - Mølgaard, Henning
AU  - Oliva, Fabrizio
AU  - Pantev, Emil
AU  - Papp, Zoltán
AU  - Perna, Gian Piero
AU  - Pfister, Roman
AU  - Piazza, Vito
AU  - Bover, Ramón
AU  - Rangel-Sousa, Diego
AU  - Recio-Mayoral, Alejandro
AU  - Reinecke, Alexander
AU  - Rieth, Andreas
AU  - Sarapohja, Toni
AU  - Schmidt, Gunter
AU  - Seidel, Mirko
AU  - Störk, Stefan
AU  - Vrtovec, Bojan
AU  - Wikström, Gerhard
AU  - Yerly, Patrik
AU  - Pollesello, Piero
PY  - 2017
DO  - 10.1016/j.ijcard.2017.05.081
UR  - http://hdl.handle.net/10668/11256
T2  - International journal of cardiology
AB  - Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hospitalizations. Heart transplantation and left ventricular assist device implantation are viable options only for a minority, and...
LA  - en
KW  - Advanced heart failure
KW  - Clinical trial
KW  - Composite end-point
KW  - Intermittent
KW  - Levosimendan
KW  - Repetitive
KW  - Administration, Oral
KW  - Cardiotonic Agents
KW  - Clinical Trials as Topic
KW  - Consensus Development Conferences as Topic
KW  - Drug Administration Schedule
KW  - Europe
KW  - Evidence-Based Medicine
KW  - Heart Failure
KW  - Humans
KW  - Hydrazones
KW  - Infusions, Intravenous
KW  - Pyridazines
KW  - Rome
KW  - Simendan
TI  - Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
TY  - research article
VL  - 243
ER  -